Equities

Beijing Sun-Novo Pharmaceutical Research Co Ltd

688621:SHH

Beijing Sun-Novo Pharmaceutical Research Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)30.06
  • Today's Change-0.09 / -0.30%
  • Shares traded2.41m
  • 1 Year change-49.85%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments721622648
Total Receivables, Net574379258
Total Inventory14137.84
Prepaid expenses482628
Other current assets, total------
Total current assets1,3571,040942
Property, plant & equipment, net246206193
Goodwill, net262626
Intangibles, net5.394.203.32
Long term investments1019540
Note receivable - long term------
Other long term assets------
Total assets1,8631,4631,243
LIABILITIES
Accounts payable573318
Accrued expenses503526
Notes payable/short-term debt385202139
Current portion long-term debt/capital leases222319
Other current liabilities, total248225216
Total current liabilities761518418
Total long term debt413450
Total debt447259208
Deferred income tax0.35----
Minority interest17127.69
Other liabilities, total3.592.835.46
Total liabilities823566481
SHAREHOLDERS EQUITY
Common stock1128080
Additional paid-in capital474500500
Retained earnings (accumulated deficit)454317182
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,040897762
Total liabilities & shareholders' equity1,8631,4631,243
Total common shares outstanding112112112
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.